Document Detail


The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.
MedLine Citation:
PMID:  6361299     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT), a multicenter, randomized, double-blind study, tested the efficacy of cholesterol lowering in reducing risk of coronary heart disease (CHD) in 3,806 asymptomatic middle-aged men with primary hypercholesterolemia (type II hyperlipoproteinemia). The treatment group received the bile acid sequestrant cholestyramine resin and the control group received a placebo for an average of 7.4 years. Both groups followed a moderate cholesterol-lowering diet. The cholestyramine group experienced average plasma total and low-density lipoprotein cholesterol (LDL-C) reductions of 13.4% and 20.3%, respectively, which were 8.5% and 12.6% greater reductions than those obtained in the placebo group. The cholestyramine group experienced a 19% reduction in risk (p less than .05) of the primary end point--definite CHD death and/or definite nonfatal myocardial infarction--reflecting a 24% reduction in definite CHD death and a 19% reduction in nonfatal myocardial infarction. The cumulative seven-year incidence of the primary end point was 7% in the cholestyramine group v 8.6% in the placebo group. In addition, the incidence rates for new positive exercise tests, angina, and coronary bypass surgery were reduced by 25%, 20%, and 21%, respectively, in the cholestyramine group. The risk of death from all causes was only slightly and not significantly reduced in the cholestyramine group. The magnitude of this decrease (7%) was less than for CHD end points because of a greater number of violent and accidental deaths in the cholestyramine group. The LRC-CPPT findings show that reducing total cholesterol by lowering LDL-C levels can diminish the incidence of CHD morbidity and mortality in men at high risk for CHD because of raised LDL-C levels. This clinical trial provides strong evidence for a causal role for these lipids in the pathogenesis of CHD.
Authors:
-
Related Documents :
24217829 - A less aggressive therapeutic option for electrical storm.
8775549 - Changes in apolipoproteins during the acute phase of kawasaki disease.
10438259 - Gemfibrozil for the secondary prevention of coronary heart disease in men with low leve...
14980229 - The next step in cardiovascular protection.
9070969 - Prognostic value of serum cholesterol level in japanese patients with coronary artery d...
12236319 - Prognosis of hypercholesterolemic patients taking pravastatin for five years: the chiba...
10536129 - Effects of socioeconomic status on access to invasive cardiac procedures and on mortali...
8370359 - Post-ischaemic cardiac dilatation and remodelling: reperfusion injury of the interstitium.
24774049 - Coronary revascularization: clinical features and indications.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  JAMA     Volume:  251     ISSN:  0098-7484     ISO Abbreviation:  JAMA     Publication Date:  1984 Jan 
Date Detail:
Created Date:  1984-02-22     Completed Date:  1984-02-22     Revised Date:  2014-09-17    
Medline Journal Info:
Nlm Unique ID:  7501160     Medline TA:  JAMA     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  351-64     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Cholesterol / blood*
Cholestyramine Resin / adverse effects,  therapeutic use*
Clinical Trials as Topic
Coronary Disease / blood,  mortality,  prevention & control*
Double-Blind Method
Humans
Hypercholesterolemia / blood,  drug therapy
Lipoproteins / blood
Male
Middle Aged
Mortality
Grant Support
ID/Acronym/Agency:
N01-HV1-2156-L/HV/NHLBI NIH HHS; N01-HV1-2160-L/HV/NHLBI NIH HHS; N01-HV2-2914-L/HV/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Lipoproteins; 0/lipoprotein cholesterol; 11041-12-6/Cholestyramine Resin; 97C5T2UQ7J/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Landmark article Oct 28, 1933. Successful removal of an entire lung for carcinoma of the bronchus. B...
Next Document:  The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduct...